Lipoxygenase

LOX

Lipoxygenases (LOXs) are a family of enzymes that are responsible for the metabolism of arachidonic and docosahexaenoic acid and for the formation of several eicosanoids and docosanoids, including leukotrienes, lipoxins and neuroprotectins. Depending on cells' redox state and other milieu conditions, these enzymes are engaged in oxidative stress and cell death mechanisms or in cell protection. Lipoxygenases are lipid peroxidizing enzymes, implicated in the pathogenesis of inflammatory and hyperproliferative diseases, which represent potential targets for pharmacological intervention.

Lipoxygenases are classified on the basis of site of arachidonate oxygenation into 5-, 8-, 9-, 11-, 12- and 15-LOX. The prominent animal LOXs are 5-LOX, 8-LOX, 12-LOX and 15-LOX, while the plant LOXs are mostly 5-LOX and 15-LOX. Among these, 5-LOX is the most predominant isoform associated with the formation of 5-hydroperoxyeicosatetraenoic acid (5-HpETE) and other bioactive lipid mediators.

Lipoxygenase Inhibitors, Antagonists & Modulators

11-Keto-beta-boswellic acid

(11-Keto-β-boswellic acid)

Cat. No.: HY-N2056

11-Keto-beta-boswellic acid (11-Keto-β-boswellic acid) is a pentacyclic triterpenic acid of the oleogum resin from the bark of the Boswellia serrate tree, popularly known as Indian Frankincense.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

15-LOX-1 inhibitor 1

Cat. No.: HY-138989

15-LOX-1 inhibitor 1 is a potent inhibitor of **15-LOX-1** (15-lipoxygenase-1) with an IC_{50} value of 0.19 μM. 15-LOX-1 inhibitor 1 protects macrophages from lipopolysaccharide-induced cytotoxicity. 15-LOX-1 inhibitor 1 inhibits NO formation and lipid peroxidation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2,5-Di-tert-butylhydroquinone

Cat. No.: HY-W012399

2,5-Di-tert-butylhydroquinone (DTBHQ), the indirect food additive, regulates the activity of **5-lipoxygenase** as well as the activity of **COX-2** (IC_{50}=1.8 and 14.1 μM for 5-LO and COX-2, respectively) .



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3-Hydroxycoumarin

Cat. No.: HY-127170

3-hydroxycoumarin is a potent and redox inhibitor of human **15-LOX-1**. 3-hydroxycoumarin is recently demonstrated to protect sea urchin reproductive cells against ultraviolet B damage.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

3-O-Acetyl-11-hydroxy-beta-boswellic acid

Cat. No.: HY-N7162

3-O-Acetyl-11-hydroxy-beta-boswellic acid is a potent 5-lipoxygenase **(5-LO)** inhibitor.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

4',5-Dihydroxyflavone

Cat. No.: HY-N1881

4',5-Dihydroxyflavone is a **soybean LOX-1** and **yeast α-Glucosidase** inhibitor, with an K_i of 102.6 μM for soybean LOX-1 and an IC_{50} of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.



Purity: 95.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

4-MMPB

Cat. No.: HY-118480

4-MMPB is a selective inhibitor of **15-lipoxygenase**, with an IC_{50} of 18 μM. 4-MMPB has IC_{50}s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

4-Nitrocatechol

Cat. No.: HY-W066890

4-Nitrocatechol is a potent **lipoxygenase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

5-Lipoxygenase-In-1

Cat. No.: HY-U00308

5-Lipoxygenase-In-1 is a **5-Lipoxygenase** inhibitor extracted from patent EP 331232 A2, table 4, compound example 4.10.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

5-O-Demethylnobiletin

(5-Demethylnobiletin)

Cat. No.: HY-N1942

5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Sideritis tragoriganum, is a direct inhibition of 5-LOX (IC_{50}=0.1 μM), without affecting the expression of COX-2.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

A-69412

Cat. No.: HY-101945

A-69412 is a reversible, specific inhibitor of the **5-lipoxygenase** (**5-LO**). A-69412 has the potential to treat asthma and ulcerative colitis, and possibly other inflammatory and allergic conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALOX15-IN-1

Cat. No.: HY-143787

ALOX15-IN-1 (compound 8b) is a potent inhibitor of the **linoleate oxygenase** activity of rabbit and human ALOX15 with $_{IC}$50s of 0.04 and 2.06 μM for ALOX15 0rthologs linoleic acid (LA) and arachidonic acid (AA), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALOX15-IN-2

Cat. No.: HY-143791

ALOX15-IN-2 (compound 8a) is a potent inhibitor of the **linoleate oxygenase** activity of rabbit and human ALOX15 with $_{IC}$50s of 1.55 and 2.79 μM for ALOX15 0rthologs linoleic acid (LA) and arachidonic acid (AA), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atreleuton

(ABT-761; VIA-2291)

Cat. No.: HY-117853

Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable **5-Lipoxygenase (5-LO)** inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

AZD 4407

(ZD 4407)

Cat. No.: HY-U00217

AZD 4407 is a potent **5-lipoxygenase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bunaprolast

(U66858)

Cat. No.: HY-U00170

Bunaprolast (U66858) is a potent inhibitor of **LTB_4** production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of **lipoxygenase** and **TXB_2** release.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Caffeic acid

Cat. No.: HY-N0172

Caffeic acid is an inhibitor of both **TRPV1** ion channel and **5-Lipoxygenase** (**5-LO**).



Purity: 98.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 5 g

CAY10698

Cat. No.: HY-121585

CAY10698 (compound 1) is a potent and selective inhibitor of **12-Lipoxygenase (12-LOX)** with an **IC_{50}** of 5.1 μM. CAY10698 is inactive against 5-LOX, 15-LOX-1, 15-LOX-2 and COX-1/2.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Chebulagic acid

Cat. No.: HY-N1996

Chebulagic acid is a **COX-LOX** dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a **M2 serine to asparagine 31 mutation (S31N)** inhibitor and influenza antiviral.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Cinnamyl-3,4-dihydroxy-α-cyanocinnamate

(CDC)

Cat. No.: HY-138688

Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent **12/15-Lipoxygenases (LO)** inhibitor. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate has the potential for the research of type 1 diabetes mellitus.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cirsiliol

Cat. No.: HY-110399

Cirsiliol is a potent and selective **5-lipoxygenase** inhibitor and a competitive low affinity benzodiazepine receptor ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CJ-13,610

Cat. No.: HY-106200

CJ-13,610, a nonredox-type **5-LO** inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC_{50} of about 70 nM. PMNL: polymorphonuclear leukocytes; AA: arachidonic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMI-392

Cat. No.: HY-19205A

CMI-392 is a dual **5-lipoxygenese** inhibitor and platelet-activating factor (**PAF**) receptor antagonist with **IC_{50}**s of 100 and 10 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMI977

(LDP977)

Cat. No.: HY-U00260

CMI977 is a potent **5-Lipoxygenase** (**5-LO**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX/5-LO-IN-1

(Atreleuton analog)

Cat. No.: HY-U00347

COX/5-LO-IN-1 (Atreleuton analog) is an inhibitor of **cylooxygenase** and **5-lipoxygenase (5-LO)**, used for the research of inflammatory and allergic disease states.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Docebenone

(AA 861)

Cat. No.: HY-12886

Docebenone (AA 861) is a potent, selective and orally active **5-LO (5-lipoxygenase)** inhibitor.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Enazadrem

Cat. No.: HY-U00024

Enazadrem is a **5-lipoxygenase** inhibitor with antiinflammatory activities.



Purity: 97.26%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FPL 62064

Cat. No.: HY-105024

FPL 62064 is a potent **5-lipoxygenase (5-LOX)** and **COX** dual inhibitor, with **IC_{50}** values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

HZ52

Cat. No.: HY-112553

HZ52 is a potent, reversible **5-lipoxygenase** inhibitor, blocking leukotriene synthesis with an **IC_{50}** of 0.7 μM in intact human polymorphonuclear leukocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ICI 211965

(ZM-211965)

Cat. No.: HY-100148

ICI 211965 (ZM-211965) is a selective and orally potent **5-Lipoxygenase** (**5-LPO**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indirubin-3'-monoxime

(Indirubin-3'-oxime)

Cat. No.: HY-19807



Indirubin-3'-monoxime is a potent **GSK-3β** inhibitor, and weakly inhibits **5-Lipoxygenase**, with IC_{50}s of 22 nM and 7.8-10 μM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC_{50}s of 100 and 180 nM.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Isothymusin

Cat. No.: HY-N3451



Isothymusin is a potent anti-oxidant agent. Isothymusin shows radical scavenging activities. Isothymusin shows anti-proliferative activities in cancer cell lines.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Licofelone

(ML-3000)

Cat. No.: HY-B1452



Licofelone (ML-3000) is a dual **COX/5-lipoxygenase (5-LOX)** inhibitor (IC_{50}=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Licofelone-d4

Cat. No.: HY-B1452S



Licofelone-d4 (ML-3000-d4) is the deuterium labeled Licofelone. Licofelone (ML-3000) is a dual **COX/5-lipoxygenase (5-LOX)** inhibitor (IC_{50}=0.21/0.18 μM, respectively) for the treatment of osteoarthritis.

Purity: >98%
Clinical Data:
Size: 5 mg

Lonapalene

(RS4317)

Cat. No.: HY-U00156



Lonapalene (RS4317) is a topically effective **5-lipoxygenase** (**5-LO**) inhibitor.

Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

LP117

Cat. No.: HY-U00438



LP117 is a novel and potent inhibitor of **5-Lipoxygenase** (**5-LO**) product synthesis with an IC_{50} of 1.1 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY 178002

Cat. No.: HY-101579



LY 178002 is a potent inhibitor of **5-lipoxygenase (5-LPO)**, **phospholipase A2**, with IC_{50} of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on **cyclooxygenase**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lycopodine

Cat. No.: HY-114372



Lycopodine, a pharmacologically important bioactive component derived from Lycopodium clavatumspores, triggers **apoptosis** by modulating **5-lipoxygenase**, and depolarizing mitochondrial membrane potential in refractory prostate cancer cells without modulating p53 activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Malotilate

(NKK 105)

Cat. No.: HY-A0060



Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the **5-lipoxygenase (5-LOX)** (IC_{50}=4.7 μM).

Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ML351

Cat. No.: HY-111310



ML351 is a potent and highly specific **15-LOX-1** inhibitor with an IC_{50} of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2.

Purity: 98.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML355

Cat. No.: HY-12341

ML355 is a potent and selective inhibitor of **12-Lipoxygenase (12-LOX)** with an IC_{50} of 0.34 μM, shows excellent selectivity over related lipoxygenases and cyclooxygenases, and possesses favorable ADME properties.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nordihydroguaiaretic acid

(NDGA)

Cat. No.: HY-N0198

Nordihydroguaiaretic acid is a **5-lipoxygenase** (**5LOX**) (IC_{50}=8 μM) and tyrosine kinase inhibitor.



Purity: 99.88%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 250 mg

Pectolinarigenin

Cat. No.: HY-N0493

Pectolinarigenin is a dual inhibitor of **COX-2/5-LOX**. Anti-inflammatory activity. Pectolinarigenin has potent inhibitory activities on melanogenesis.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

PF-4191834

(PF-04191834)

Cat. No.: HY-117048

PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the **5-Lipoxygenase (5-LOX)** (IC_{50}=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective...



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PGS-IN-1

(KME-4)

Cat. No.: HY-101587

PGS-IN-1 is a potent inhibitor of **prostaglandin synthetase** (PGS) with an IC_{50} of 0.28 μM; also inhibits **5-lipoxygenase** with an IC_{50} of 1.05 μM.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Phenethyl ferulate

Cat. No.: HY-W009248

Phenethyl ferulate is a major constituent ofQianghuo, shows inhibitory activity against **cyclooxygenase** (**COX**) and **5-lipoxygenase** (**5-LOX**) with IC_{50} values of 4.35 μM and 5.75 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Phenidone

Cat. No.: HY-W010144

Phenidone, an orally active dual inhibitor of **cyclooxygenase (COX)** and **lipoxygenase (LOX)**, ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Picrinine

Cat. No.: HY-N2074

Picrinine, an akuammiline alkaloid, is isolated from the leaves of Alstonia scholaris. Picrinine exhibits anti-inflammatory activity through inhibition of the 5-lipoxygenase enzyme.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Psoralidin

Cat. No.: HY-N0232

Psoralidin is a dual inhibitor of **COX-2** and **5-LOX**, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties. Psoralidin significantly downregulates **NOTCH1** signaling.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

REV 5901

Cat. No.: HY-112532

REV 5901 is a competitive and orally active antagonist of **leukotriene receptor**, with a K_i of 0.7 μM. REV 5901 is also a **5-lipoxygenase** inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Ro 3-1314

(9a,12a-Octadecadiynoic acid)

Cat. No.: HY-N8276

Ro 3-1314 (9a,12a-Octadecadiynoic acid) is a plant **lipoxygenase** inhibitor. Ro 3-1314 is a linoleic acid metabolism inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RWJ 63556

Cat. No.: HY-U00022

RWJ 63556 is an orally active **COX-2 selective/5-lipoxygenase** inhibitor, with anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S-(+)-Marmesin

((+)-Marmesin; (S)-Marmesin)

Cat. No.: HY-N2176

S-(+)-Marmesin is a natural coumarin, exhibiting **COX-2/5-LOX** dual inhibitory activity.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S-2474

Cat. No.: HY-19212

S-2474 is an inhibitor of **COX-2** and **5-lipoxygenase (5-LO)**, with IC_{50}s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tepoxalin

Cat. No.: HY-13219

Tepoxalin is a dual inhibitor of COX and 5-lipoxygenase (5-LO) with potent anti-inflammatory activity and a favorable gastrointestinal profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Terameprocol

(EM-1421)

Cat. No.: HY-10447

Terameprocol is a synthetic derivative of Nordihydroguaiaretic acid and a non-selective **lipoxygenase** inhibitor. Terameprocol has antiviral and antitumor effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

U-73122

Cat. No.: HY-13419

U-73122 is a **phospholipase C (PLC)** and **5-LO (5-lipoxygenase)** inhibitor with an $IC_{50}$of 1-2.1 μM for PLC.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Wedelolactone

Cat. No.: HY-N0551

Wedelolactone, a natural product from Ecliptae herba, suppresses LPS-induced **caspase-11** expression by directly inhibiting the IKK Complex. Wedelolactone inhibits **5-lipoxygenase** (**5-Lox**) (IC_{50}~2.5 μM) activity by an oxygen radical scavenging mechanism.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Xanthatin

Cat. No.: HY-N3032

Xanthatin is isolated from Xanthium strumarium leaves.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YS121

Cat. No.: HY-111140

YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (**mPGES-1**; IC_{50}=3.4 μM) and 5-lipoxygenase (**5-LOX**; IC_{50}=6.5 μM). YS121 dose- dependently reduces PGE2 production with EC_{50}=12 μM in IL-1β-stimulated A549 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zileuton

(A 64077; Abbott 64077) **Cat. No.:** HY-14164

Zileuton is a potent and selective inhibitor of **5-lipoxygenase** with antiasthmatic properties.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Zileuton sodium

(A 64077 sodium; Abbott 64077 sodium) **Cat. No.:** HY-14164A

Zileuton sodium (A 64077 sodium) is a potent and selective inhibitor of **5-lipoxygenase**, exhibiting inflammatory activities.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Zileuton-d4

Cat. No.: HY-14164S

Zileuton-d4 (A 64077-d4) is the deuterium labeled Zileuton. Zileuton (A 64077) is a potent and selective inhibitor of **5-lipoxygenase** with antiasthmatic properties.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

β-Boswellic acid

Cat. No.: HY-N2513

β-Boswellic acid is isolated from the gum resin of Boswellia serrate. β-Boswellic acid is a nonreducing-type inhibitor of the 5-lipoxygenase (**5-LO**) product formation either interacting directly with the 5-LO or blocking its translocation.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg